Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 8, Issue 5

Issues

Volume 10 (2015)

Prevalence and reasons for non-adherence to hyperlipidemia treatment

Przemyslaw Kardas
Published Online: 2013-09-18 | DOI: https://doi.org/10.2478/s11536-013-0198-x
  • [1] Pajak A, Wiercinska E, Polakowska M, Kozakiewicz K, Kaczmarczyk-Chalas K, Tykarski A et al. Rozpowszechnienie dyslipidemii u mezczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63:6 (supl. 4); S1–6 Google Scholar

  • [2] Bandosz P, Flaherty M O’, Drygas W, Koziarek J, Wyrzykowski B, Rutkowski M et al. Explaining the decline in coronary heart disease mortality in Poland between 1991 and 2005. Eur Heart J. 2010, 31 (Abstract Suppl.), 167 Google Scholar

  • [3] Sabate E (red). Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003 Google Scholar

  • [4] Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152 http://dx.doi.org/10.1001/archinte.165.10.1147CrossrefGoogle Scholar

  • [5] Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–467 http://dx.doi.org/10.1001/jama.288.4.462CrossrefGoogle Scholar

  • [6] Wisniowska B, Skowron A. Evaluation of patients’ adherence to statins In Poland. Curr Med Res Opin. 2011; 27(1): 99–105 http://dx.doi.org/10.1185/03007995.2010.536745CrossrefGoogle Scholar

  • [7] Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009; 65(10): 1013–1024 http://dx.doi.org/10.1007/s00228-009-0673-0Web of ScienceCrossrefGoogle Scholar

  • [8] Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297(2): 177–186 http://dx.doi.org/10.1001/jama.297.2.177CrossrefGoogle Scholar

  • [9] Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012 Jan;34(1):190–199 http://dx.doi.org/10.1016/j.clinthera.2011.12.011CrossrefGoogle Scholar

  • [10] Poluzzi E, Piccinni C, Carta P, Puccini A, Lanzoni M, Motola D et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011; 67(4): 407–414 http://dx.doi.org/10.1007/s00228-010-0958-3Web of ScienceGoogle Scholar

  • [11] Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient Prefer Adherence. 2012; 6: 323–329 http://dx.doi.org/10.2147/PPA.S29353CrossrefGoogle Scholar

  • [12] Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, for the ABC Project Team. A new taxonomy for describing and defining adherence to medications. Brit J Clin Pharmacol 2012; 73(5), 691–705. DOI: 10.1111/j.1365-2125.2012.04167.x http://dx.doi.org/10.1111/j.1365-2125.2012.04167.xCrossrefGoogle Scholar

  • [13] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff 2011; 30(1): 91–99 http://dx.doi.org/10.1377/hlthaff.2009.1087CrossrefGoogle Scholar

  • [14] Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011; 32(3): 264–268 http://dx.doi.org/10.1093/eurheartj/ehq297CrossrefGoogle Scholar

  • [15] DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42(3): 200–209 http://dx.doi.org/10.1097/01.mlr.0000114908.90348.f9CrossrefGoogle Scholar

  • [16] Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010; 4(6): 462–471 http://dx.doi.org/10.1016/j.jacl.2010.08.026Web of ScienceCrossrefGoogle Scholar

  • [17] Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008; 14(6 Suppl B): 9–15 Google Scholar

  • [18] Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens. 1993; 11(12): 1403–1411 http://dx.doi.org/10.1097/00004872-199312000-00013CrossrefGoogle Scholar

  • [19] Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B; for the ABC project team. Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis. Drugs. 2013 Apr 16. DOI 10.1007/s40265-013-0041-3 CrossrefWeb of ScienceGoogle Scholar

  • [20] Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011; 107(11): 1662–1666 http://dx.doi.org/10.1016/j.amjcard.2011.01.052Web of ScienceCrossrefGoogle Scholar

  • [21] Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes. Ann Pharmacother. 2011; 45(3): 342–349 http://dx.doi.org/10.1345/aph.1P539CrossrefGoogle Scholar

  • [22] Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy. 2001; 21(5): 576–582 http://dx.doi.org/10.1592/phco.21.6.576.34541CrossrefGoogle Scholar

About the article

Published Online: 2013-09-18

Published in Print: 2013-10-01


Citation Information: Open Medicine, Volume 8, Issue 5, Pages 539–547, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0198-x.

Export Citation

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Nouh Harsha, Magor Papp, László Kőrösi, Árpád Czifra, Róza Ádány, and János Sándor
International Journal of Environmental Research and Public Health, 2019, Volume 16, Number 20, Page 3797

Comments (0)

Please log in or register to comment.
Log in